MetabolicRETATRUTIDE
10MG
$100
Description
Retatrutide is a groundbreaking triple receptor agonist that simultaneously activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-action mechanism represents the most advanced approach in metabolic peptide research, addressing appetite regulation, insulin sensitivity, and energy expenditure through three complementary pathways. The GLP-1 component suppresses appetite and slows gastric emptying, GIP enhances insulin sensitivity and fat metabolism, while the glucagon component increases energy expenditure and promotes fat oxidation in the liver.
Potential Benefits
Research Notes
Phase 2 clinical trial results published in the New England Journal of Medicine (2023) demonstrated unprecedented metabolic outcomes, with participants achieving up to 24.2% body weight reduction at the highest dose over 48 weeks. Retatrutide's glucagon receptor activity distinguishes it from dual agonists like tirzepatide, adding energy expenditure and hepatic fat oxidation to the appetite-suppressing effects of GLP-1/GIP. Phase 3 trials are ongoing.
Usage Information
For research and educational purposes only. Consult with a qualified professional before use.
All peptides must be refrigerated upon receipt.
RESEARCH PURPOSES ONLY
This product is intended for research and educational purposes only. Not intended for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.